Pharma commercial intelligence, news & analysis

Evaluate gives you the understanding and time you need to drive better decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

How we can help you

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual EvaluatePharma World Preview.

OUR PRODUCTS

EvaluatePharma

Get a global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2024 and the first single view of the risk and reward of the R&D landscape from EvaluatePharma Vision.

OUR SERVICES

Custom Solutions

Improve your strategic decision-making with customised solutions that draw on our team of industry experts and trusted commercial intelligence.

October 19, 2018

Esmo 2018 – Encouraging early prostate data fail to lift Clovis

Response rates in BRCA-positive patients hint at Parp inhibitors’ potential in prostate cancer, but Clovis reins in hopes for a different genetic marker.

October 17, 2018

Roche leaves Abbott in the dust when it comes to US approval times

The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.

October 19, 2018

Upcoming events – Takeda awaits Dengue data and Regenxbio needs more heartening results

October 18, 2018

Novartis quietly kicks the canakinumab can down the road